Skip to content

Multi-Center Clinical Study on Novel Bio-Enhanced Internal Fixation for Osteoporotic Proximal Humeral Fractures

Multi-Center Clinical Study on Novel Bio-Enhanced Internal Fixation for Osteoporotic Proximal Humeral Fractures

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500111311
Enrollment
Unknown
Registered
2025-10-29
Start date
2025-10-30
Completion date
Unknown
Last updated
2025-11-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Osteoporotic proximal humeral fracture (OPHF)

Interventions

Group B:Internal fixation using the novel bio-enhanced plate system.
Group A :Traditional locking steel plate PHILOS steel plate system is used for internal fixation.
Group C:Internal fixation with the novel bio-enhanced system combined with injectable calcium phosphate artificial bone.

Sponsors

Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
60 Years to 85 Years

Inclusion criteria

Inclusion criteria: 1. Aged 60-85 years; 2. Diagnosed with an acute, closed Neer three- or four-part proximal humeral fracture by X-ray and CT scan; 3. A bone mineral density T-score of <= -2.5 SD as measured by dual-energy X-ray absorptiometry (DXA), or a T-score of <= -2.0 SD in the presence of a history of fragility fracture; 4. Time from injury to scheduled surgery <= 2 weeks; 5. Voluntarily participate in the study and provide signed informed consent;

Exclusion criteria

Exclusion criteria: 1. Pathological fractures or concomitant severe fractures at other sites. 2. Previous surgical history, deformity, or dysfunction in the affected shoulder joint. 3. Associated injuries to the axillary nerve or brachial plexus. 4. Severe cardiac, cerebral, pulmonary, hepatic, or renal insufficiency, rendering the patient unable to tolerate surgery. 5. Allergy to artificial bone materials or internal fixation implants. 6. Concomitant neurological disorders affecting bone metabolism or functional outcomes (e.g., rheumatoid arthritis, Parkinson's disease). 7. Long-term use of corticosteroids or immunosuppressants. 8. Cognitive impairment, unable to cooperate with follow-up and rehabilitation. 9. Expected survival of less than 1 year. 10. Concurrent participation in other clinical trials that may interfere with the results of this study.

Design outcomes

Secondary

MeasureTime frame
Disability Score;Safety Assessment;Imaging Assessment ;Visual Analog Scale (VAS);

Primary

MeasureTime frame
Constant-Murley Score;

Countries

China

Contacts

Public ContactSu Jiacan

Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine

jiacansu@126.com+86 21 25077955

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026